Head-to-head evidence
afimkibart vs tulisokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TL1A · full Ulcerative Colitis pipeline
afimkibart
Developed by Roche and partners
NCT04090411 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled Phase 2 study (N=246) in moderate-to-severe ulcerative colitis, with Week 14 clinical remission on the Mayo score as the primary endpoint. Although remission rates were numerically higher in all afimkibart dose groups (25.5%, 23.3%, 23.9%) than placebo (11.6%), the differences were not statistically significant (one-sided p-values 0.055–0.082; 90% confidence intervals crossed zero), so the primary efficacy comparison was not met. The well-controlled design is real evidence, but because the primary endpoint was missed, the trial does not rise to strong evidence of benefit.
Next expected readout: October 2026 · NCT06588855 (registry estimate)
tulisokibart
Developed by Merck & Co.
NCT06052059 · Phase 3 · active, not recruiting
First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2037 · NCT06651281 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: afimkibart's landscape · tulisokibart's landscape